Frontal Lobe Hemorrhage With Surrounding Edema and Subarachnoid Hemorrhage

Megan Vu 1, Mustafa Mohamed 2, Thor S. Stead 3, Rohan Mangal 4, Latha Ganti 5, 6, 7

Abstract

We report the case of an 81-year-old woman who presented with a left hemineglect, a rightward gaze preference, and baseline disorientation. Her National Institutes of Health Stroke Score was 4. Her medical history was significant for dementia, osteoporosis, dyslipidemia, and a previous stroke. CT revealed a right-sided frontal lobe hemorrhage with surrounding edema and subarachnoid hemorrhage. Laboratory evaluation was significant for leukocytosis. The etiologies, clinical presentation, and diagnosis of this often devastating type of stroke are presented. While she did have a significant neurologic deficit (neglect), she was able to remain alert and protect her airway. Her hospital course consisted of observation in the ICU and blood pressure management. The case illustrates that intracerebral hemorrhage (ICH) can sometimes present indolently and does not always require surgical intervention.

Introduction

Intracerebral hemorrhage (ICH) accounts for 15% of all strokes and 50% of stroke-related mortality, which equates to approximately 2.8 million deaths globally every year [1]. In 2010, hemorrhagic strokes accounted for nearly a third of 35 million stroke cases and had a mortality rate of just over 50% worldwide. Two major risk factors for ICH are age and anticoagulant use. The overall increase in life expectancy means a larger aging population, which translates to an increased incidence of ICH. ICH is more prevalent in older persons, and older persons are also more likely to be on an anticoagulant agent.

Other risk factors for ICH are being part of non-white ethnicity, being male, older age, and having familial apolipoprotein syndromes [2, 3]. Other risk factors also include cerebral amyloid angiopathy, uncontrolled or untreated hypertension, and drug abuse (i.e. alcohol, nicotine, and cocaine) [4]. Additional risk factors such as platelet inhibition related to COX-1 enzyme inhibitors (such as aspirin) and P2Y12 purinoreceptor antagonists (such as clopidogrel, ticagrelor, prasugrel, and cangrelor) have been described [5].

Patients who suffer an ICH may display symptoms such as a sudden onset focal neurological deficit, followed by a decrease in the level of consciousness, which can be measured with the Glasgow Coma Scale (GCS). Other symptoms include severe headache, nausea, vomiting, convulsive and non-convulsive seizures, and elevated blood pressure [6].

Case Presentation

An 81-year-old female presented to the emergency department alongside her daughter who described the patient as being less socially interactive and refusing to engage in her usual activities. The patient’s daughter reported generalized weakness and confusion. These symptoms began 2-3 days prior according to her best estimate. The daughter denied any history of trauma or head injury. She stated her mother did not have fever, headache, or other symptoms. The patient required assistance for all activities of daily living but was normally able to interact with friends and family, and engaged in several hobbies. She had occasional episodes of psychomotor agitation in the evenings and was prone to getting lost in familiar places, even inside her own home.

Her medical history was significant for dementia, osteoporosis, dyslipidemia, and a previous stroke. Her past medical history includes a cesarean section and hysterectomy; her family history includes cancer and heart disease. She denies alcohol or recreational drug use. She was a former smoker, one pack per day for 60 years.

Her temperature was 98.6°F, pulse 84 beats per minute, blood pressure 105/66 mmHg, oxygen saturation 98% on room air, and respiratory rate 18 breaths per minute.
The patient’s physical examination revealed a frail but alert lady with a left hemineglect, rightward gaze preference, and baseline disorientation. Her National Institutes of Health Stroke Score was 4. Laboratory analysis was essentially unremarkable, except for a very mildly elevated white blood cell count (Table 1).

| Laboratory Test                      | Reference Range   | Test Result |
|--------------------------------------|-------------------|-------------|
| **Chemistry**                        |                   |             |
| Sodium                               | 136 - 145 mmol/L  | 137         |
| Potassium                            | 3.7 - 5.1 mmol/L  | 4.1         |
| Chloride                             | 98 - 107 mmol/L   | 104         |
| Carbon Dioxide                       | 21 - 32 mmol/L    | 25          |
| Blood Urea Nitrogen                  | 7 - 18 mg/dl      | 20 H        |
| Creatinine                           | 0.55 - 1.3 mg/dl  | 1.13        |
| Glucose                              | 74 - 106 mg/dl    | 104         |
| Calcium                              | 8.4 - 10.1 mg/dl  | 9.4         |
| Total Bilirubin                      | 0.2 - 1.5 mg/dl   | 0.7         |
| Aspartate aminotransferase           | 10 - 37 unit/L    | 20          |
| Alanine aminotransferase             | 12 - 78 unit/L    | 21          |
| Total Alkaline Phosphatase           | 45 - 117 unit/L   | 81          |
| Troponin I                           | < 54 ng/L         | 6           |
| Total Protein                        | 6.4-8.2 g/dL      | 8.1         |
| Albumin                              | 3.4 - 5.0 g/dL    | 3.6         |
| Triglycerides                        | < 150 mg/dL       | 61          |
| Cholesterol                          | < 200 mg/dL       | 167         |
| Low Density Lipoprotein (LDL) Cholesterol | < 100 mg/dL     | 81          |
| High Density Lipoprotein (HDL) Cholesterol | > 50 mg/dL     | 74.0        |
| Thyroid Stimulation Hormone 3rd Generation | 0.36 - 3.74 mIU/mL | 1.06       |
| **Coagulation Studies**              |                   |             |
| Prothrombin time (PT)                | 10.0 - 12.8 seconds | 12.1       |
| International Normalized Ratio (INR)| 0.8 - 1.1         | 1.1         |
| Partial Thromboplastin Time (PTT)    | 25 - 38 seconds   | 29.5        |
| **Hematology**                       |                   |             |
| White Blood Cell count               | 4.0 - 10.5 \times 10^3 /uL | 11.8 H     |
| Red Blood Cell count                 | 3.93 - 5.22 \times 10^6/uL | 3.95       |
| Hemoglobin                           | 11.2 - 15.7 g/dL  | 11.8        |
| Hematocrit                           | 34.1 - 44.9%      | 35.1        |
| Platelet Count                       | 150 - 400 \times 10^3 / uL | 300        |
| Immature Granulocytes %              | 0.0 - 0.4%        | 0.3         |
| Neutrophils %                        | 34.0 - 71.1%      | 64.0        |
| Lymphocytes %                        | 19.3 - 51.7%      | 24.3        |
| Monocytes %                          | 4.7 - 12.5%       | 10.9        |
| Eosinophils %                        | 0.7 - 5.8%        | 0.1 L       |
The patient’s brain CT demonstrated a 2.6 cm high posterior right frontal lobe hemorrhage with adjacent edema and subarachnoid blood. There was no mass effect by the hemorrhage or surrounding edema upon the right lateral ventricle (Figure 1).

**FIGURE 1:** Axial (panel A) and sagittal (panel B) views of brain CT scans demonstrating right-sided intracerebral hemorrhage (ICH) located around the frontal and parietal lobes (arrow)

The CT angiography (CTA) of her head and neck was negative for any aneurysm or arteriovenous malformation. The patient was admitted to the ICU where she had hourly neurologic checks. Systolic blood pressure was maintained between 140 and 160 mmHg. As the patient was improving spontaneously, neurosurgical intervention for craniectomy and hematoma evacuation was deferred. The patient was discharged home on day 5.

**Discussion**

The location of the ICH is often helpful when trying to decipher the etiology of the hemorrhage. Subcortical and infratentorial hemorrhages are associated with hypertensive vasculopathy. Lobar and supratentorial hemorrhages, especially in patients older than age 55 are often associated with cerebral amyloid angiopathy. A review of risk factors for ICH based on the Framingham study revealed a significant association between lobar hemorrhage with hypertension, elevated systolic blood pressure, and apolipoprotein E (APOE) 4 allele homozygous status [7]. Interestingly, our patient neither had a history of hypertension nor did she have elevated blood pressure on presentation. Furthermore, her imaging demonstrates perihemorrhagic edema, which usually portends poorer outcomes. However, the patient did well despite the edema. Of note, corticosteroids were not used for our patient with edema secondary to ICH, as opposed to edema in the setting of neoplasm or cerebral infection.

With regards to sex, there is still conflicting literature about outcomes and mortality [8]. Several studies point to higher morbidity and mortality in women with ICH secondary to the presence of intraventricular hemorrhage [9,10]. However, a 2020 European study analyzing the results of the INTERACT 1 and 2 trial noted that possible under-representation of women and data being based on single-center studies may account for uncertainty in outcomes between men and women [11]. There does, however, appear to be sex-related differences in the management of ICH. A study comparing patients who had deep infratentorial hemorrhages (locations that would be difficult for surgical intervention) found men and women to have similar rates of hydrocephalus, intraventricular hemorrhage, and ventricular shift. Even with the correction of radiographic and clinical features, men were three times more likely to have an extra-ventricular drain placed as compared to women [12]. This difference, however, was not seen when comparing hematoma evacuation rates.
Some of the known risk factors for hematoma expansion include symptom onset to initial CT imaging, higher initial ICH volumes, concurrent antplatelet and anticoagulant usage, and the presence of contrast extravasation on CTA, also known as the ‘spot sign’ [13,14]. Of note, ICH volume is the strongest predictor of 30-day mortality regardless of hematoma location. When obtained within the first few hours of the first presentation, having a spot sign coincided with hematoma expansion in 77% of patients, compared to only 4%-22% without a spot sign [15]. There are other signs on imaging that portend hematoma expansion, including an irregular shape and homogenous density, the ‘swirl sign’ (seen in panel A of our patient’s brain CTA), evidence of a fluid level, a ‘satellite sign’ (high-density starry dots around the ICH) as well as the ‘blend sign’ (a relatively hypoattenuating area and adjacent hyperattenuating region) [16-18].

There are several surgical options for hematoma evacuation. Generally, these are considered beneficial only in patients who have signs of brainstem compression, hydrocephalus, or acute neurologic deterioration [19]. Our patient presented in a relatively stable condition, did not have major hemodynamic compromise, and was protecting her airway. In her case, observation resulted in improvement, thus no surgical intervention was undertaken.

Conclusions

We present the case of an 81-year-old woman with ICH. The location of her ICH was lobar, thus amyloid angiopathy is a likely etiology. While she did have a significant neurologic deficit (neglect), she was able to remain alert and protect her airway. Her hospital course consisted of observation in the ICU and blood pressure management. Her symptoms improved significantly, with near resolution of her neglect. The case illustrates the use of imaging for prognostication and assessment of etiology. Despite the perihemorrhagic edema, in this case, the patient ultimately ended up doing well. The case is somewhat unusual in that the patient did not have a history of hypertension and was not hypertensive on arrival.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. HCA Centralized Algorithms for Research Rules on IRB Exemptions (CARRIE) IRB issued approval 2022-509. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare-affiliated entity. The views expressed in this publication are those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities.

References

1. Schrag M, Kirshner H: Management of intracerebral hemorrhage: JACC focus seminar. J Am Coll Cardiol. 2020, 75:1819-31. 10.1016/j.jacc.2019.10.066.
2. Rajashekar D, Liang JW: Intracerebral Hemorrhage. StatPearls Publishing, Treasure Island, FL; 2022.
3. Qureshi AI, Mendelow AD, Hanley DF: Intracerebral haemorrhage. Lancet. 2009, 373:1632-44. 10.1016/S0140-6736(09)60371-8
4. Elliott J, Smith M: The acute management of intracerebral hemorrhage: a clinical review. Anesth Analg. 2010, 110:1419-27. 10.1213/ANE.0b013e3181d56b8c
5. Garg R, Biller J: Recent advances in spontaneous intracerebral hemorrhage. F1000Res. 2019, 8:302. 10.12688/f1000research.16357.1
6. Flower O, Smith M: The acute management of intracerebral hemorrhage. Curr Opin Crit Care. 2011, 17:106-14. 10.1097/MCC.0b013e32834d823.
7. Lioutas VA, Beiser AS, Aparicio HJ, Himmel JJ, Selim MH, Romero JR, Seshadri S: Assessment of incidence and risk factors of intracerebral hemorrhage among participants in the Framingham Heart Study between 1948 and 2016. JAMA Neurol. 2020, 77:1252-60. 10.1001/jamaneurol.2020.1512
8. Marini S, Moretti A, Ayres AM, et al.: Sex differences in intracerebral hemorrhage expansion and mortality. J Neurol Sci. 2017, 379:112-6. 10.1016/j.jns.2017.05.057
9. Craen A, Mangal R, Stead TG, Ganti L: Gender differences in outcomes after non-traumatic intracerebral hemorrhage. Cureus. 2019, 11:e5818. 10.7759/cureus.5818
10. Ganti L, Jain A, Yerragonda N, Jain M, Bellolio MF, Gilmore RM, Rabinstein A: Female gender remains an independent risk factor for poor outcome after acute nontraumatic intracerebral hemorrhage. Neurol Res Int. 2013, 2013:219907. 10.1155/2013/219907
11. Sandset EC, Wang X, Carcel G, et al.: Sex differences in treatment, radiological features and outcome after intracerebral haemorrhage: pooled analysis of Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage trials 1 and 2. Eur Stroke J. 2020, 5:345-50. 10.1177/2396873209575313
12. Li Q, Yang WS, Wang XC, et al.: Blend sign predicts poor outcome in patients with intracerebral
13. Wang SS, Bögli SY, Nierobisch N, Wildbolz S, Keller E, Brandi G: Sex-related differences in patients' characteristics, provided care, and outcomes following spontaneous intracerebral hemorrhage. Neurocrit Care. 2022, 57:111-20. 10.1007/s12028-022-01455-y

14. Al-Shahi Salman R, Frantzias J, Lee RJ, et al.: Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Neurocrit Care. 2018, 21(2):88-94. 10.1007/s12028-017-0712-0

15. Goldstein JN, Fazen LE, Snider R, et al.: Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology. 2007, 68:889-94. 10.1212/01.wnl.0000257087.22852.21

16. Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, et al.: Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol. 2012, 11:307-14. 10.1016/S1474-4422(12)70038-8

17. Ng D, Churilov L, Mitchell P, Dowling R, Yan B: The CT swirl sign is associated with hematoma expansion in intracerebral hemorrhage. AJNR Am J Neuroradiol. 2018, 39:232-7. 10.3174/ajnr.A5465

18. Shimoda Y, Ohtomo S, Arai H, Okada K, Tominaga T: Satellite sign: a poor outcome predictor in intracerebral hemorrhage. Cerebrovasc Dis. 2017, 44:105-12. 10.1159/000477179

19. Morotti A, Goldstein JN: Diagnosis and management of acute intracerebral hemorrhage. Emerg Med Clin North Am. 2016, 34:883-99. 10.1016/j.emc.2016.06.010